PGC1 alpha: an emerging therapeutic target for chemotherapy-induced peripheral neuropathy

Zhai, Mingzhu1,5; Hu, Haibei1; Zheng, Yi1; Wu, Benqing1; Sun, Wuping2,3,4

2023

10.1177/17562864231163361

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS   影响因子和分区

1756-2856

1756-2864

Chemotherapy-induced peripheral neuropathy (CIPN)-mediated paresthesias are a common complication in cancer patients undergoing chemotherapy. There are currently no treatments available to prevent or reverse CIPN. Therefore, new therapeutic targets are urgently needed to develop more effective analgesics. However, the pathogenesis of CIPN remains unclear, and the prevention and treatment strategies of CIPN are still unresolved issues in medicine. More and more studies have demonstrated that mitochondrial dysfunction has become a major factor in promoting the development and maintenance of CIPN, and peroxisome proliferator-activated receptor gamma (PPAR?) coactivator 1a (PGC1a) plays a significant role in maintaining the mitochondrial function, protecting peripheral nerves, and alleviating CIPN. In this review, we highlight the core role of PGC1a in regulating oxidative stress and maintaining normal mitochondrial function and summarize recent advances in its therapeutic effects and mechanisms in CIPN and other forms of peripheral neuropathy. Emerging studies suggest that PGC1a activation may positively impact CIPN mitigation by modulating oxidative stress, mitochondrial dysfunction, and inflammation. Therefore, novel therapeutic strategies targeting PGC1a could be a potential therapeutic target in CIPN.

chemotherapy-induced peripheral neuropathy mitochondrial biogenesis mitochondrial dysfunction oxaliplatin oxidative stress paclitaxel PGC1 alpha

SCI

英语

其他

National Natural Science Foundation of China[82171378] ; Shenzhen Municipal Science, Technology and Innovation Commission["JCYJ20210324112202006","JCYJ20220531094815034"] ; Medical and Health Science and Technology Plan Project of Shenzhen Yantian District Science and Technology Innovation Bureau[YTWS20220208]

Neurosciences & Neurology

Clinical Neurology

WOS:000958703300001

SAGE PUBLICATIONS LTD

Web of Science

1.Univ Chinese Acad Sci, Shenzhen Hosp, Ctr Med Expt CME, Shenzhen 518016, Peoples R China
2.Shenzhen Univ, Hlth Sci Ctr, Dept Pain Med, Shenzhen 518060, Peoples R China
3.Shenzhen Univ, Shenzhen Nanshan Peoples Hosp, Hlth Sci Ctr, Shenzhen Municipal Key Lab Pain Med, Shenzhen 518060, Peoples R China
4.Shenzhen Univ, Affiliated Hosp 6, Hlth Sci Ctr, Shenzhen 518060, Peoples R China
5.Southern Univ Sci & Technol, Yantian Hosp, Shenzhen, Peoples R China

Zhai, Mingzhu,Hu, Haibei,Zheng, Yi,et al. PGC1 alpha: an emerging therapeutic target for chemotherapy-induced peripheral neuropathy[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS,2023,16.

Zhai, Mingzhu,Hu, Haibei,Zheng, Yi,Wu, Benqing,&Sun, Wuping.(2023).PGC1 alpha: an emerging therapeutic target for chemotherapy-induced peripheral neuropathy.THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS,16.

Zhai, Mingzhu,et al."PGC1 alpha: an emerging therapeutic target for chemotherapy-induced peripheral neuropathy".THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS 16(2023).